StoxGlaxosmithkline Pharmaceuticals vs Narayana Hrudayalaya: share price & financials comparison
NSE: GLAXO vs NH · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Glaxosmithkline Pharmaceuticals vs Narayana Hrudayalaya at a glance
Glaxosmithkline Pharmaceuticals (GLAXO) has a market capitalisation of ₹42,773 Cr, against ₹38,890 Cr for Narayana Hrudayalaya (NH). Over the past year Narayana Hrudayalaya has returned +5.7%, compared with -4.5% for Glaxosmithkline Pharmaceuticals. On valuation, Narayana Hrudayalaya trades at a lower P/E of 45.3 versus 83.0. Glaxosmithkline Pharmaceuticals earns a higher return on equity (27.4% vs 17.2%). Glaxosmithkline Pharmaceuticals comes out ahead on size and profitability. Narayana Hrudayalaya comes out ahead on valuation, growth, momentum and technicals. Across the scored metrics below, Glaxosmithkline Pharmaceuticals leads on 5 and Narayana Hrudayalaya on 11. On StoxGud's 10-point checklist, Glaxosmithkline Pharmaceuticals scores 7/10 and Narayana Hrudayalaya scores 7/10.
| Metric | Glaxosmithkline Pharmaceuticals | Narayana Hrudayalaya |
|---|---|---|
| Size | ||
| Market cap | ₹42,773 Cr | ₹38,890 Cr |
| Revenue (latest FY) | ₹3,822 Cr | ₹7,896 Cr |
| Net profit (latest FY) | ₹1,036 Cr | ₹806 Cr |
| Valuation | ||
| P/E | 83.0 | 45.3 |
| P/B | 22.74 | 7.77 |
| Dividend yield | 1.67% | 0.23% |
| Profitability | ||
| Return on equity | 27.4% | 17.2% |
| Net profit margin | 12.4% | 8.4% |
| Operating margin | 34.1% | 18.5% |
| Growth | ||
| Revenue growth (YoY) | +20.8% | +73.0% |
| Net profit growth (YoY) | — | +16.5% |
| Revenue CAGR (multi-year) | +2.9% | +25.0% |
| Financial health | ||
| Debt to equity | 0.00 | 0.99 |
| Momentum | ||
| 1-month return | -4.1% | +10.4% |
| 1-year return | -4.5% | +5.7% |
| 3-year CAGR | +20.8% | +22.4% |
| 5-year CAGR | +8.6% | +28.5% |
| 10-year CAGR | +6.1% | +18.7% |
| Distance from 52W high | -18.7% | -8.5% |
| Technicals | ||
| RSI (14) | 46 | 71 |
| Price vs 200-day avg | +0.3% | +3.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Glaxosmithkline Pharmaceuticals | Narayana Hrudayalaya |
|---|---|---|
| Price above 50-day average | ✗ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✓ | ✗ |
| Positive 1-year return | ✗ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Glaxosmithkline Pharmaceuticals or Narayana Hrudayalaya?
Glaxosmithkline Pharmaceuticals has a market cap of ₹42,773 Cr and Narayana Hrudayalaya has a market cap of ₹38,890 Cr as of 06 Nov 2026.
Which has a lower P/E, Glaxosmithkline Pharmaceuticals or Narayana Hrudayalaya?
Narayana Hrudayalaya has the lower P/E: Glaxosmithkline Pharmaceuticals trades at 83.0 and Narayana Hrudayalaya at 45.3.
Which gave better returns in the last year, Glaxosmithkline Pharmaceuticals or Narayana Hrudayalaya?
Narayana Hrudayalaya did better: Glaxosmithkline Pharmaceuticals returned -4.5% and Narayana Hrudayalaya returned +5.7% over one year.
Is Glaxosmithkline Pharmaceuticals or Narayana Hrudayalaya a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Glaxosmithkline Pharmaceuticals scores 7/10 and Narayana Hrudayalaya scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.